Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"ProBioGen","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ProBioGen inks next Commercial GlymaxX\u00ae License with Roche","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"},{"orgOrder":0,"company":"ProBioGen","sponsor":"Lava Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ProBioGen, Lava Therapeutics Sign Cell Line Mfg. Pact","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"},{"orgOrder":0,"company":"ProBioGen","sponsor":"Heidelberg Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Heidelberg Pharma contracts ProBioGen for Cell Line Development and Manufacturing Services","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"ProBioGen","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ProBioGen Licenses GlymaxX\u00ae Technology to AbbVie","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"},{"orgOrder":0,"company":"ProBioGen","sponsor":"Asher Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Asher Biotherapeutics Contracts ProBioGen to Develop and Manufacture Their Lead Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"ProBioGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProBioGen\u2019s Vaccine Production Cell Line AGE1.CR.pIX\u00ae Used for Clinical Production","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"ProBioGen","sponsor":"ImmunOs Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"ProBioGen","sponsor":"Nouscom AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nouscom Reaches Clinical Phase II Using ProBioGen\u2019s AGE1.CR.pIX\u00ae Production Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"ProBioGen","sponsor":"DIOSynVax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ProBioGen Partners with DIOSynVax to Manufacture Trivalent Hemorrhagic Fever Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by ProBioGen

    Menu

    ProBioGen

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              ProBioGen

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ProBioGen Partners with DIOSynVax to Manufacture Trivalent Hemorrhagic Fever Vaccine

              Details:

              The partnership aims to support the DIOSynVax product DIOS-HFVac3 vaccine for clinical advancement. It is being evaluated in the preclinical trial studies for the treatment of viral hemorrhagic fevers.

              Lead Product(s): DIOS-HFVac3

              Therapeutic Area: Infections and Infectious Diseases Product Name: DIOS-HFVac3

              Highest Development Status: Preclinical Product Type: Vaccine

              Partner/Sponsor/Collaborator: DIOSynVax

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership March 27, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ProBioGen

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nouscom Reaches Clinical Phase II Using ProBioGen’s AGE1.CR.pIX® Production Platform

              Details:

              Nous-209 is based on a heterologous prime/boost regimen composed of the Great Ape Adenovirus GAd20-209-FSP used for priming and Modified Vaccinia virus Ankara MVA-209-FSP used for boosting.

              Lead Product(s): GAd20-209-FSP,MVA-209-FSP,Pembrolizumab

              Therapeutic Area: Oncology Product Name: Nous-209

              Highest Development Status: Phase II Product Type: Vaccine

              Recipient: Nouscom AG

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 04, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ProBioGen

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients

              Details:

              ProBioGen and ImmunOs extends their partnership for further large-scale manufacturing of clinical material for IOS-1002, a first-in-class, multi-functional agent based on a naturally occurring human leukocyte antigen, ImmunOs' lead program for the treatment of cancer.

              Lead Product(s): IOS-1002,Pembrolizumab

              Therapeutic Area: Oncology Product Name: IOS-1002

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: ImmunOs Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership April 12, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ProBioGen

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ProBioGen’s Vaccine Production Cell Line AGE1.CR.pIX® Used for Clinical Production

              Details:

              VAC85135, an investigational viral vector-based cancer vaccine for hematological malignancies. The MVA-based component of the vaccine was produced using ProBioGen's AGE1.CR.pIX.

              Lead Product(s): VAC85135,Ipilimumab

              Therapeutic Area: Oncology Product Name: VAC85135

              Highest Development Status: Phase I Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 20, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ProBioGen

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Asher Biotherapeutics Contracts ProBioGen to Develop and Manufacture Their Lead Candidate

              Details:

              ProBioGen to provide cell line development, process development and GMP manufacturing at 1000 L bioreactor scale of Asher's lead immuno-oncology candidate, AB248.

              Lead Product(s): AB248

              Therapeutic Area: Oncology Product Name: AB248

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: Asher Bio

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration April 26, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ProBioGen

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ProBioGen Licenses GlymaxX® Technology to AbbVie

              Details:

              The unique advantage of the GlymaxX® technology is that a single GlymaxX® modified cell line is sufficient to produce both, completely fucosylated or afucosylated antibodies and those with an intermediate defined fuscosylation level.

              Lead Product(s): Afucosylated antibodies

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: AbbVie Inc

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement January 21, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ProBioGen

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Heidelberg Pharma contracts ProBioGen for Cell Line Development and Manufacturing Services

              Details:

              ProBioGen is conducting the full service package from cell line development using its CHO.RiGHT® cell line expression platform, incl over process development till GMP manufacturing of the mAb intermediates of Heidelberg Pharma’s ATAC molecules for cancer indications.

              Lead Product(s): Antibody-targeted Amanitin-Conjugate

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Heidelberg Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement October 22, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ProBioGen

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ProBioGen, Lava Therapeutics Sign Cell Line Mfg. Pact

              Details:

              Under the agreement and using its CHO.RiGHT™ expression platform, ProBioGen will conduct cell line development of a ?? T-cell engaging bispecific antibody format.

              Lead Product(s): Vγ9Vδ2 T cells based antibodies

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Large molecule

              Recipient: Lava Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement January 14, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ProBioGen

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ProBioGen inks next Commercial GlymaxX® License with Roche

              Details:

              ProBioGen AG, has signed a commercial license agreement with Roche for applying ProBioGen’s proprietary GlymaxX® technology to boost the antibody’s ADCC anti-tumor activity.

              Lead Product(s): GlymaxX

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement January 08, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY